A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions

Healthy

Interventions

DRUG

ZYIL1 Capsule

NLRP3 inflammasome inhibitor

Trial Locations (1)

Zydus Research Centre, Ahmedabad

All Listed Sponsors

lead

Zydus Lifesciences Limited

INDUSTRY